Skip to content

Replimune Group REPL Professional Service Fees Payable

Professional Service Fees Payable at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Immunovant, Inc. logo
Immunovant, Inc.IMVT
GRAIL, Inc. logo
GRAIL, Inc.GRAL

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's professional service fees payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's professional service fees payable?
Replimune Group (REPL) reported professional service fees payable of $569K in Q4 2025.
How has Replimune Group's professional service fees payable changed year-over-year?
Replimune Group's professional service fees payable increased by 29.9% year-over-year, from $438K to $569K.
What is the long-term trend for Replimune Group's professional service fees payable?
Over 4 years (2021 to 2025), Replimune Group's professional service fees payable has grown at a -20.7% compound annual growth rate (CAGR), from $407K to $161K.